ICER: Madrigal’s Resmetirom Looks More Cost-Effective In NASH Than Intercept’s OCA

 
• By Joseph Haas
Economic review
ICER's draft review of leading NASH candidates finds some cost benefit for one • Source: Shutterstock

More from Drug Pricing

More from Scrip